| Identification | Back Directory | [Name]
BMS-986020 | [CAS]
1257213-50-5 | [Synonyms]
AM152
CS-2492
BMS-986020
BMS-986020;BMS 986020;BMS986020
1-{4'-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid
(R)-1-(4'-(3-methyl-4-(((1-phenylethoxy)carbonyl)amino)isoxazol-5-yl)-[1,1'-biphenyl]-4-yl)cyclopropane-1-carboxylic acid
Cyclopropanecarboxylic acid, 1-[4'-[3-methyl-4-[[[(1R)-1-phenylethoxy]carbonyl]amino]-5-isoxazolyl][1,1'-biphenyl]-4-yl]- | [Molecular Formula]
C29H26N2O5 | [MDL Number]
MFCD30489743 | [MOL File]
1257213-50-5.mol | [Molecular Weight]
482.53 |
| Chemical Properties | Back Directory | [Melting point ]
174-180°C | [Boiling point ]
664.8±55.0 °C(Predicted) | [density ]
1.309±0.06 g/cm3(Predicted) | [storage temp. ]
-20°C Freezer | [solubility ]
DMSO (Slightly), Methanol (Slightly, Sonicated) | [form ]
Solid | [pka]
4.19±0.20(Predicted) | [color ]
White to Off-White | [InChIKey]
GQBRZBHEPUQRPL-LJQANCHMSA-N | [SMILES]
C1(C2=CC=C(C3=CC=C(C4ON=C(C)C=4NC(O[C@@H](C4=CC=CC=C4)C)=O)C=C3)C=C2)(C(O)=O)CC1 |
| Hazard Information | Back Directory | [Description]
BMS 986020 is a potent G protein-coupled lysophosphatidic acid receptor 1 (LPA1) antagonist with an IC50 value less than 300 nM for human LPA1 expressing CHO cells.1 Formulations containing BMS 986020 are being investigated in clinical trials for efficacy in idiopathic pulmonary fibrosis.2 | [Uses]
BMS-?986020 is an LPA-1 antagonist which may be used in the inhibition and treatment of bleomycin-induced pulminary fibrosis. | [References]
[1] PETER T. W. CHENG*. Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA1) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases[J]. Journal of Medicinal Chemistry, 2021, 64 21: 15549-15581. DOI: 10.1021/acs.jmedchem.1c01256
[2] VEERESA GUDUDURU . Identification of Darmstoff analogs as selective agonists and antagonists of lysophosphatidic acid receptors[J]. Bioorganic & Medicinal Chemistry Letters, 2006, 16 2: Pages 451-456. DOI: 10.1016/j.bmcl.2005.08.096
[3] L. SIVARAMAN . Structure dependence and species sensitivity of in vivo hepatobiliary toxicity with lysophosphatidic acid receptor 1 (LPA1) antagonists[J]. Toxicology and applied pharmacology, 2022, 438: Article 115846. DOI: 10.1016/j.taap.2021.115846
[4] BHAKTA PRASAD GAIRE Ji W C Arjun Sapkota. BMS-986020, a Specific LPA1 Antagonist, Provides Neuroprotection against Ischemic Stroke in Mice.[J]. Antioxidants, 2020, 9 11. DOI: 10.3390/antiox9111097 |
|
|